Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IIA Breast Cancer AJCC v6 and v7: early-phase trial registry
1 of 12 indexed Stage IIA Breast Cancer AJCC v6 and v7 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 1 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Stage IIA Breast Cancer AJCC v6 and v7: 12 US clinical trials tracked, 1 recruiting.
Stage IIA Breast Cancer AJCC v6 and v7 is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition stage-iia-breast-cancer-ajcc-v6-and-v7
OPEN 1 | RECR 8% | LATE 2 | EARLY 7 | RANK #1429 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Allergic Rhinitis (8% recruiting · 24 trials)
Stage IIA Breast Cancer AJCC v6 and v7 lists 1 open slots (8% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IIA Breast Cancer AJCC v6 and v7 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IIA Breast Cancer AJCC v6 and v7 is recruiting below its size-band peers.
1 of 12 indexed trials (8.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IIA Breast Cancer AJCC v6 and v7 research.
M.D. Anderson Cancer Center accounts for 7 of 12 trials (58.3%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Stage IIA Breast Cancer AJCC v6 and v7 enrolment sits around 280 participants.
Median target enrolment is 280 among the 12 trials that report a genuine target (sentinel values excluded). 2 of those (16.7%) plan for fewer than 100 participants.
-
Stage IIA Breast Cancer AJCC v6 and v7 research is mostly interventional.
12 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
M.D. Anderson Cancer Center
NCT02945579
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
National Cancer Institute (NCI)
NCT00310180
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT02912312
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
M.D. Anderson Cancer Center
NCT02276443
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
NCT01266642
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Academic and Community Cancer Research United
NCT03012100
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
M.D. Anderson Cancer Center
NCT01245712
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
M.D. Anderson Cancer Center
NCT02754752
The Role of Lifestyle Factors in Breast Cancer-Related Outcomes
M.D. Anderson Cancer Center
NCT02079662
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
National Cancer Institute (NCI)
NCT03317405
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
NCT01275677
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
NCT02654119
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IIA Breast Cancer AJCC v6 and v7 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IIA Breast Cancer AJCC v6 and v7 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IIA Breast Cancer AJCC v6 and v7 page
12 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage IIA Breast Cancer AJCC v6 and v7 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage IIA Breast Cancer AJCC v6 and v7 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IIA Breast Cancer AJCC v6 and v7 condition card totals 12 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.